BIOSANTE PHARMACEUTICALS INC Form 8-K September 25, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 24, 2003

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-28637 (Commission File Number) 58-2301143 (I.R.S. Employer Identification Number)

(State or Other Jurisdiction of Incorporation)

> 111 Barclay Boulevard Lincolnshire, Illinois (Address of Principal Executive Offices)

60069 (Zip Code)

(847) 478-0500

(Registrant s Telephone Number, Including Area Code)

N/A (Former Name or Former Address, If Changed Since Last Report)

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

Item 5. Other Events

On September 25, 2003, BioSante Pharmaceuticals, Inc. issued a press release, a copy of which is attached as an exhibit hereto, announcing that on the evening of September 24, 2003, BioSante Pharmaceuticals, Inc. received a notice that it was approved for listing on the American Stock Exchange and expects that its common stock will begin trading on the American Stock Exchange under the ticker symbol BPA at the opening of trading on October 1, 2003. Our common stock will continue to trade on the Over-the-Counter Bulletin Board under the ticker symbol BISP until the closing of trading on September 30, 2003.

Item 7. Financial Statements and Exhibits.

(a)	Financial Statements of Businesses Acquired.
	· · · ·

Not Applicable

(b) Pro Forma Financial Information.

Not Applicable

(c) Exhibits.

Exhibit No.

Ex. 99.1

Press Release dated September 25, 2003 (filed herewith electronically).

Description

2

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 25, 2003 BIOSANTE PHARMACEUTICALS, INC.

By:

/s/ Phillip B. Donenberg Phillip B. Donenberg *Chief Financial Officer, Treasurer and Secretary*

3

BIOSANTE PHARMACEUTICALS, INC.

FORM 8-K

<u>Exhibit Index</u>

Exhibit No.	Description	Method of Filing
99.1	Press Release of BioSante Pharmaceuticals, Inc. issued September 25, 2003.	Filed herewith electronically

4